

Prescription Medication Recall

Natpara® (parathyroid hormone) for injection

About this recall.

Your safety, health and well-being are important to us. We want to let you know that **on September 5, 2019, Takeda* announced a voluntary, nationwide recall of all doses of Natpara® (parathyroid hormone) for injection because of a product issue.**

As of September 5, 2019, these are the doses affected by this recall:

Medication name	Strength	NDC #
Natpara (parathyroid hormone) injection	25 mcg	68875-0202-02
	50 mcg	68875-0203-02
	75 mcg	68875-0204-02
	100 mcg	68875-0205-02

Why this medication was recalled.

It was discovered that when the septum is punctured (or poked) each day over the course of the 14-day treatment, small rubber pieces may fall off and get into the cartridge. **It's important to know that as of September 5th, Takeda hasn't received any complaints or information about medical illness or harmful effects caused by the recalled medication.**

What this medication are used to treat.

Natpara is a prescription parathyroid hormone used with calcium and vitamin D to control low blood calcium (hypocalcemia) in people with low parathyroid hormone blood levels (hypoparathyroidism). It is only for people who do not respond well to treatment with calcium and active forms of vitamin D alone, because it may increase the possible risk of bone cancer (osteosarcoma).

Here's what you can do if your medication was recalled.

- **Call OnePath® at 866.888.0660.** Representatives are available Monday through Friday, 8:30 am to 8:00 pm EST. You may also get a phone call from a OnePath Patient Support Manager to talk about your concerns and/or answer any questions you have about this recall.
- **Call your doctor's office to find out how this affects your health and/or treatment, and/or if you've had any recent problems with this medication.** Only you and your doctor can decide what's best for your treatment. We've also let your doctor know that you may have been affected by this recall.
- **Go to Takeda's website to learn more about the recall and next steps.** You can type this address into your web browser: <https://www.takeda.com/newsroom/newsreleases/2019/takeda-issues-us-recall-of-natpara-parathyroid-hormone-for-injection-due-to-the-potential-for-rubber-particulate/>



We're here if you need us.

Please call your doctor's office if you have questions about how this recall affects your health and/or treatment.

If you're a Cigna customer and have a question about your coverage or benefits, please call the number on your Cigna ID card. We're available anytime, 24/7/365.

Together, all the way.®



* Natpara is made and distributed by Shire-NPS Pharmaceuticals, Inc., part of the Takeda Group.

Para obtener ayuda en español llame al número en su tarjeta de Cigna.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

918808 Natpara_Recall_Posted Online_09/19 © 2019 Cigna.